September 27, 2022Open Access

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Key Points

Key points are not available for this paper at this time.

Abstract

Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.

Bookmark

View Full Paper

Cite This Study

Atkins et al. (Tue,) studied this question.

synapsesocial.com/papers/69d968a394760e72e6a3c5d1 https://doi.org/https://doi.org/10.1200/jco.22.01763

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The State of Melanoma: Emergent Challenges and Opportunities2021 · 108 citations
2Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial2016 · 1,005 citations
3Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination2021 · 974 citations
4LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study2021 · 30 citations
5Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 0672021 · 36 citations

Bookmark

View Full Paper